“Cash is king”
Zealand Pharma has raised USD 50 million to support the advancement of the Danish biotech’s pipeline. According to CEO David Solomon there are several specific goals the money will help the company achieve.
BY STEFAN SINGH KAILAY
Zealand Pharma has previously announced that it was increasing its focus on advancing the company’s assets without commercial partners, and with the recent announcement that Zealand had secured USD 50 million in royalty bond financing, the company is set to put its money where its mouth is.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Business chief to leave Zealand Pharma
For abonnenter
Analyst: Promising Zealand candidate
For abonnenter
